Unasnemab (MT-3921), a humanized IgG1 monoclonal antibody, exerts its biological effects by binding to the repulsive guidance molecule A (RGMa), which in turn enhances locomotor function and promotes neuroregeneration. Unasnemab (MT-3921) demonstrates potential utility in the field of spinal cord injury research, where it provides an experimental approach to explore regenerative therapies targeting inhibitory guidance molecules.